FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089739923> ?p ?o ?g. }

• W3089739923 endingPage "342" @default.
• W3089739923 startingPage "341" @default.
• W3089739923 abstract "The translational evolution of GU cancer care has thus far largely centered on the improvement of radiograph-assisted diagnosis and in combination therapeutic strategies. We dedicate this issue to the recent progresses made and challenges faced in prostate cancer (PC) care. The implement of multiparametric Magnetic Resonance Imaging (mpMRI) and the ensuing standardized report according to Prostate Imaging Reporting And Data System (PI-RADS) has improved both sensitivity and specificity in biopsy diagnosis of clinically significant prostate cancer (csPC) beyond PSA and digital examination, and is changing practice guideline.1Weinreb J.C. Barentsz J.O. Choyke P.L. et al.PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.Eur Urol. 2016; 69: 16-40Abstract Full Text Full Text PDF PubMed Scopus (1914) Google Scholar, 2Kim H. Pak S. Park K.J. et al.Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?.Clin Genitourin Cancer. 2020; 18: 50-55Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar, 3Jiang G. Zhang G. Chen S. Chen M. Targeted and Systematic Prostate Biopsy in Biopsy-naive Men With Positive Multiparameter Magnetic Resonance Imaging Findings: A Meta-analysis.Clin Genitourin Cancer. 2020; 18: 105-110.e105Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar In the article “Performing precise biopsy in naive patients with equivocal PI-RADs v2 category 3 lesions: an MRI-based nomogram to avoid unnecessary surgical intervention”, Zhang et al reported that more PC were detected in the transitional zone in PI-RADS 3 patients and the positive predictive value of a positive Apparent Diffusion Coefficient (ADC < 900 μm2/s) was further improved upon the incorporation of PSA density into the nomogram. Hence, unnecessary biopsy could be avoided in equivocal transitional zone lesions with negative ADC.4Zhang Y. Zeng N. Zhang F.B. et al.Performing precise biopsy in naive patients with equivocal PI-RADS, version 2, score 3, lesions: An MRI-based nomogram to avoid unnecessary surgical intervention.Clin Genitourin Cancer. 2020; 18: 367-377Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar Along the same line, the article “Combination of multiparametric magnetic resonance imaging with elastic-fusion biopsy has a high sensitivity in detecting clinically significant prostate cancer in daily practice” Cecchini et al reported the concordance of MRI-IL (index lesion) and csPC by mpMRI especially in the peripheral zone.5Cecchini S. Castellani D. Fabbietti P. et al.Combination of multiparametric magnetic resonance imaging with elastic-fusion biopsy has a high sensitivity in detecting clinically significant prostate cancer in daily practice.Clin Genitourin Cancer. 2020; 18 (e501-9)Abstract Full Text Full Text PDF Scopus (5) Google Scholar The principal systemic treatment options for metastatic Castration-Resistant PC (mCRPC) are anti-androgens, chemotherapeutic drugs, Sipuleucel-T, and Radium-223.6George D.J. Sartor O. Miller K. et al.Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.Clin Genitourin Cancer. 2020; 18: 284-294Abstract Full Text Full Text PDF PubMed Scopus (56) Google Scholar In the article “A Systematic Review and Network Meta-Analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-Resistant Prostate Cancer” Hird et al summarized that non-steroidal anti-androgens (NSAA) also improved survival of high-risk nmCRPC.7Hird A.E. Magee D.E. Bhindi B. et al.A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.Clin Genitourin Cancer. 2020; 18: 343-350Abstract Full Text Full Text PDF PubMed Scopus (28) Google Scholar In the article “Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer” Shore et al reported the safety and tolerability of this novel combination therapy, and the improvements in quality of life and pain without unexpected toxicities nor increases in falls, fractures, or deaths.8Shore N.D. Schellhammer P.F. Tutrone R.F. et al.Open label Phase II study of enzalutamide with concurrent administration of radium 223 dichloride in patients with castration-resistant prostate cancer.Clin Genitourin Cancer. 2020; 18: 416-422Abstract Full Text Full Text PDF Scopus (4) Google Scholar Recent biomarker studies of mCRPC supported further evaluations of androgen receptor splice variant, AR-V7, and TP53 gain-of-function mutations in resistance to androgen-axis targeted therapies.9Zhang T. Karsh L.I. Nissenblatt M.J. Canfield S.E. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.Clin Genitourin Cancer. 2020; 18: 1-10Abstract Full Text Full Text PDF PubMed Scopus (41) Google Scholar,10Chapman L. Ledet E.M. Barata P.C. et al.TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.Clin Genitourin Cancer. 2020; 18: 148-154Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar In the article “Diagnostic Performance of the Prostate Cancer Antigen 3 Test in Prostate Cancer: Systematic Review and Meta-analysis” Lee et al summarized PCA3 test results across 54 studies (17,575 patients) and discussed its moderate sensitivity (0.71) and specificity (0.68) in the diagnosis of PC.11Lee D. Shim S.R. Ahn S.T. et al.Diagnostic performance of the prostate cancer antigen 3 test in prostate cancer: systematic review and meta-analysis.Clin Genitourin Cancer. 2020; 18 (.e5): 402-408Abstract Full Text Full Text PDF Scopus (10) Google Scholar Major challenges are the recent negative early trial results of promising novel mechanism-based new effective systemic agents in mCRPC, including IGF-1R inhibitor Cixutumumab and P450c17a inhibitor INO-464 Seviteronel12Madan R.A. Schmidt K.T. Karzai F. et al.Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.Clin Genitourin Cancer. 2020; 18: 258-267.e251Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar,13McHugh D.J. Chudow J. DeNunzio M. et al.A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.Clin Genitourin Cancer. 2020; 18: 171-178.e172Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar; and the inconsistent standard of care as reported by Kodiyan et al in “Radical Prostatectomy Without Pelvic Lymph Node Dissection Widely Practiced Despite Poorer Survival” in which the care of 66,469 unfavorable risk PC patients were analyzed, and despite significant survival benefit associated with PLND ∼40% of patients did not receive PLND.14Kodiyan J. Guirguis A. Ashamalla H. Radical prostatectomy without pelvic lymph node dissection is widely practiced in high-risk patients despite poorer survival.Clin Genitourin Cancer. 2020; 18 (.e8): 395-401Abstract Full Text Full Text PDF Scopus (2) Google Scholar In the article “Neoadjuvant Gemcitabine-Cisplatin plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: a 12-year experience” Iyer et al concluded that neoadjuvant gemcitabine-cisplatin (GC) achieves meaningful pathologic response and patients with ≥ pT2 residual disease, positive margins, or positive LN post-chemotherapy have inferior survival.15Iyer G. Tully C.M. Zabor E.C. et al.Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic pymph node dissection for muscle-invasive bladder cancer: A 12-year experience.Clin Genitourin Cancer. 2020; 18: 387-394Abstract Full Text Full Text PDF Scopus (22) Google Scholar In the article “Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Magnetic Resonance Imaging (MRI) for Staging of Muscle-Invasive Bladder Cancer (MIBC)” Eulitt et al reported similar performance of FDG-PET/MRI and CT in evaluating primary tumors and lymph node involvement of MIBC.16Eulitt P.J. Altun E. Sheikh A. et al.Pilot study of [18F] fluorodeoxyglucose positron emission tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for staging of muscle-invasive bladder cancer (MIBC)..Clin Genitourin Cancer. 2020; 18: 378-386Abstract Full Text Full Text PDF Scopus (9) Google Scholar In the article “Could bladder multiparametric MRI be introduced in routine clinical practice? Role of the new VI-RADS score: results from a prospective study” Marchioni et al conducted a prospective study using mpMRI in discriminating non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), and demonstrated the use of VI-RADS a standard reporting method appealing in future clinical practice.17Marchioni M. Primiceri G. Pizzi A.D. et al.Could bladder multiparametric MRI be introduced in routine clinical practice? role of the new VI-RADS score: results from a prospective study.Clin Genitourin Cancer. 2020; 18 (.e1): 409-415Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar In the article “Programmed Death-1, Programmed Death -Ligand 1 inhibitors in advanced and recurrent urothelial carcinoma: A meta-analysis of single-agent studies” Tafuri et al performed a meta-analysis on 10 eligible studies consisting of 1934 patients, and reported the objective response rate at 18% for second line or above therapies, seemingly more favorable than other salvage therapies.18Tafuri A. Smith D.D. Cacciamani G.E. et al.Programmed death 1 and programmed death ligand 1 inhibitors in advanced and recurrent urothelial carcinoma: meta-analysis of single-agent studies.Clin Genitourin Cancer. 2020; 18 (.e3): 351-360Abstract Full Text Full Text PDF PubMed Scopus (10) Google Scholar Our most recent “The 2020 Kidney Cancer Treatment Sequence Issue” discussed the tremendous progress made in metastatic kidney cancer care over the past 15 years.19Hsieh J.J. The 2020 Kidney Cancer Treatment Sequence Issue.Clin Genitourin Cancer. 2020; 18: 241-243Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar In a Case Series article Reimers et al reported the feasibility of “Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients with Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma”, and discussed the surgical challenges of nephrectomy after CPI immunotherapy.20Reimers M.A. Figenshau R.S. Kim E.H. et al.Elective cytoreductive nephrectomy after checkpoint inhibitor immunotherapy in patients with initially unresectable metastatic clear cell renal cell carcinoma.Clin Genitourin Cancer. 2020; 18: 361-366Abstract Full Text Full Text PDF Scopus (6) Google Scholar" @default.
• W3089739923 created "2020-10-08" @default.
• W3089739923 creator A5021734597 @default.
• W3089739923 date "2020-10-01" @default.
• W3089739923 modified "2023-09-25" @default.
• W3089739923 title "The 2020 Prostate Cancer Issue" @default.
• W3089739923 cites W1827911007 @default.
• W3089739923 cites W2975059798 @default.
• W3089739923 cites W2975133332 @default.
• W3089739923 cites W2981085590 @default.
• W3089739923 cites W2984677026 @default.
• W3089739923 cites W2993770666 @default.
• W3089739923 cites W2999047517 @default.
• W3089739923 cites W2999516414 @default.
• W3089739923 cites W3003502784 @default.
• W3089739923 cites W3005037398 @default.
• W3089739923 cites W3006463018 @default.
• W3089739923 cites W3009112563 @default.
• W3089739923 cites W3009812442 @default.
• W3089739923 cites W3010833790 @default.
• W3089739923 cites W3011383765 @default.
• W3089739923 cites W3012530095 @default.
• W3089739923 cites W3013013514 @default.
• W3089739923 cites W3016380505 @default.
• W3089739923 cites W3020773137 @default.
• W3089739923 cites W3047000463 @default.
• W3089739923 doi "https://doi.org/10.1016/j.clgc.2020.09.001" @default.
• W3089739923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33010875" @default.
• W3089739923 hasPublicationYear "2020" @default.
• W3089739923 type Work @default.
• W3089739923 sameAs 3089739923 @default.
• W3089739923 citedByCount "1" @default.
• W3089739923 countsByYear W30897399232022 @default.
• W3089739923 crossrefType "journal-article" @default.
• W3089739923 hasAuthorship W3089739923A5021734597 @default.
• W3089739923 hasBestOaLocation W30897399231 @default.
• W3089739923 hasConcept C121608353 @default.
• W3089739923 hasConcept C126322002 @default.
• W3089739923 hasConcept C143998085 @default.
• W3089739923 hasConcept C2780192828 @default.
• W3089739923 hasConcept C71924100 @default.
• W3089739923 hasConceptScore W3089739923C121608353 @default.
• W3089739923 hasConceptScore W3089739923C126322002 @default.
• W3089739923 hasConceptScore W3089739923C143998085 @default.
• W3089739923 hasConceptScore W3089739923C2780192828 @default.
• W3089739923 hasConceptScore W3089739923C71924100 @default.
• W3089739923 hasIssue "5" @default.
• W3089739923 hasLocation W30897399231 @default.
• W3089739923 hasOpenAccess W3089739923 @default.
• W3089739923 hasPrimaryLocation W30897399231 @default.
• W3089739923 hasRelatedWork W2221425694 @default.
• W3089739923 hasRelatedWork W2365364931 @default.
• W3089739923 hasRelatedWork W2418638721 @default.
• W3089739923 hasRelatedWork W2810602217 @default.
• W3089739923 hasRelatedWork W2915965072 @default.
• W3089739923 hasRelatedWork W2962601203 @default.
• W3089739923 hasRelatedWork W4243514755 @default.
• W3089739923 hasRelatedWork W4295763953 @default.
• W3089739923 hasRelatedWork W2189427681 @default.
• W3089739923 hasRelatedWork W2530851007 @default.
• W3089739923 hasVolume "18" @default.
• W3089739923 isParatext "false" @default.
• W3089739923 isRetracted "false" @default.
• W3089739923 magId "3089739923" @default.
• W3089739923 workType "article" @default.